UPDATE: Exelixis Deal with Bristol-Myers Pushes Company Deeper into Oncology | GenomeWeb

This story has been updated from a previous version.

NEW YORK, July 18 - With its sights set on joining the ranks of big pharma--at least in the field of oncology--Exelixis said Wednesday that it had signed a far-reaching deal with Bristol-Myers Squibb to jointly discover potential drug targets for cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.